Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 37,410 shares, a drop of 29.6% from the February 26th total of 53,146 shares. Based on an average daily volume of 40,491 shares, the days-to-cover ratio is currently 0.9 days. Approximately 6.0% of the shares of the company are sold short.

Artelo Biosciences Stock Up 230.4%

Shares of NASDAQ:ARTL opened at $10.54 on Friday. Artelo Biosciences has a 12-month low of $2.95 and a 12-month high of $85.80. The stock has a market cap of $7.80 million, a PE ratio of -0.17 and a beta of 1.04. The business has a 50 day moving average of $4.64 and a 200-day moving average of $7.22.

Key Stories Impacting Artelo Biosciences

Here are the key news stories impacting Artelo Biosciences this week:

• Positive Sentiment: Announced a private placement to raise approximately $11.0 million in gross proceeds (3,188,407 shares and warrants), with warrants exercisable at $3.20 and potential additional proceeds if exercised — provides near-term cash for working capital and to repay bridge debt. Article Title
• Neutral Sentiment: Requested withdrawal of the recently effective S-1 registration statement — market reaction has been bullish but the company did not publicly frame the strategic reason; this may simply reflect a change in financing approach (private placement vs. registered offering). Article Title
• Neutral Sentiment: Multiple LULD (Limit Up/Limit Down) pauses and trading halts were recorded throughout the day — this is a mechanical response to sharp intraday moves and explains the repeated short interruptions in trading. (Internal Nasdaq halt records observed.)
• Negative Sentiment: The financing is priced well below recent trading levels and includes long-dated warrants, which could meaningfully dilute current shareholders if exercised; issuance under at-the-market rules and the exercise terms increase share count risk and investor uncertainty about long-term capital needs. Article Title

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a report on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $54.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.